Pancreatic Cancer Research

ResearcherPeking University Cancer HospitalActive in the last 2 years

Lin Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8101-4129; OpenAlex author ID A5030200922. Sources: ClinicalTrials.gov.

Their work

Papers
2
Trials
9 (principal investigator on 8)
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 trial · 2020: 1 trial · 2021: 1 trial · 2022: 1 paper, 1 trial · 2023: 2 trials · 2024: none · 2025: 1 paper, 2 trials

Papers 2

  1. Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia. Co-author DOI 10.1016/j.esmogo.2025.100158↗
  2. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗

Trials 9

  1. A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors Study director NCT07069062↗
  2. A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation Principal investigator NCT07259590↗
  3. A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Principal investigator NCT05830097↗
  4. A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC) Principal investigator NCT06197178↗
  5. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor Principal investigator NCT05262491↗
  6. The Transformation of Locally Advanced Pancreatic Cancer. Principal investigator NCT04723030↗
  7. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics Principal investigator NCT04584008↗
  8. Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. Principal investigator NCT03874897↗
  9. SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer Principal investigator NCT01811277↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 1 shared paper, 2025 · strength 0.25
  2. Kyu‐pyo Kim · 1 shared paper, 2025 · strength 0.25
  3. Masafumi Ikeda · 1 shared paper, 2025 · strength 0.25
  4. Do‐Youn Oh · 1 shared paper, 2025 · strength 0.25
  5. Stephen Lam Chan · 1 shared paper, 2025 · strength 0.25
  6. Sang Myung Woo · 1 shared paper, 2025 · strength 0.25
  7. Feng Jiao · 1 shared paper, 2022 · strength 0.09
  8. Zheng Wang · 1 shared paper, 2022 · strength 0.09
  9. Zhiwei Li · 1 shared paper, 2022 · strength 0.09
  10. Tao Zhang · 1 shared paper, 2022 · strength 0.09
  11. Qingyong Ma · 1 shared paper, 2022 · strength 0.09
  12. Liwei Wang · 1 shared paper, 2022 · strength 0.09
  13. Chunyi Hao · 1 shared paper, 2022 · strength 0.09
  14. Gang Ren · 1 shared paper, 2022 · strength 0.09
  15. Jie Chen · 1 shared paper, 2022 · strength 0.09
  16. Dan Cao · 1 shared paper, 2022 · strength 0.09
  17. Jian Wang · 1 shared paper, 2022 · strength 0.09
  18. Yongrui Bai · 1 shared paper, 2022 · strength 0.09
  19. Zhihong Zhang · 1 shared paper, 2022 · strength 0.09
  20. Yongwei Sun · 1 shared paper, 2022 · strength 0.09
  21. Ji Li · 1 shared paper, 2022 · strength 0.09
  22. Jianping Xiong · 1 shared paper, 2022 · strength 0.09
  23. Jun Zhou · 1 shared paper, 2022 · strength 0.09
  24. Feng‐Hua Wang · 1 shared paper, 2022 · strength 0.09
  25. Leizhen Zheng · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.